Casirivimab and imdevimab combination invited for COVID-19
M
Casirivimab and imdevimab combination invited for COVID-19.
Casirivimab and imdevimab combination invited for COVID-19.
Tocilizumab and sarilumab invited for COVID-19.
On 05 February 2021, Gilead Sciences Ltd.
On 13 November 2020, WHO listed the nOPV2 vaccine (Bio Farma, Indonesi
WHO Prequalification Unit - Medicines Assessment Team (PQT/MED) has been in contact with Sanofi regarding the presence of 1-cyclopentyl-4-nitrosopiperazine (CPNP) in their tuberculosis treatment -
Nitrosamine impurities have been identified in rifapentine and rifampicin products.
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
Medicine Regulatory Authorities firs
WHO Prequalification Unit (PQT) added the below new product to its prequalified list: